新广益IPO前大专学历两兄弟豪揽2.2亿分红，哥哥任董事长、弟弟任董事

Group 1 - The core business of the company is focused on the research, development, production, and sales of high-performance specialty functional materials, including anti-bleed specialty films and high-resistance specialty films [2] - The company achieved revenues of 455 million yuan, 516 million yuan, and 657 million yuan for the years 2022, 2023, and 2024 respectively, with net profits of 81.51 million yuan, 83.28 million yuan, and 116 million yuan during the same period [2][3] - As of the end of the reporting period, the total assets of the company were 836.05 million yuan, with a total equity attributable to the parent company of 678.76 million yuan, and a debt-to-asset ratio of 18.95% [3] Group 2 - The company has a strong focus on research and development, with R&D expenses accounting for 4.72% of operating revenue in 2024 [3] - The company’s major shareholders, Xia Chaohua and Xia Huachao, collectively control 85.54% of the voting rights [3] - The company has a history of cash dividends, with a distribution of 220 million yuan from undistributed profits approved by shareholders in November 2021 [5] Group 3 - The company’s board of directors includes key figures such as Xia Chaohua as Chairman and Li Yongsheng as General Manager, with their terms running from February 2025 to February 2028 [5] - Xia Chaohua has extensive experience in various roles within the company since its inception, contributing to its strategic direction and operational management [8][9] - Xia Huachao has also held multiple positions in different companies, indicating a strong background in business management [10]